Publications by authors named "C Minoia"
Patient diagnosed with lymphoma presents a greater risk of infection, mainly if undergoing anti-CD20 therapy, splenectomized, hypogammaglobulinemic. They can therefore benefit from a vaccination program, especially in the watchful waiting phases or before starting oncologic treatment. The COVID-19 pandemic has raised awareness on vaccinations in frail patients, but a homogeneous approach has yet to be achieved across different vaccinations.
View Article and Find Full Text PDFArticle Synopsis
- The IELSG37 trial investigated whether patients with primary mediastinal B-cell lymphoma (PMBCL) who have a complete metabolic response (CMR) after treatment can safely skip consolidation radiotherapy.
- It was a randomized noninferiority study involving 545 patients, focusing on progression-free survival (PFS) over 30 months, with results showing high PFS rates of 96.2% for observation and 98.5% for radiotherapy.
- The study concluded that avoiding irradiation does not negatively impact survival, highlighting positive outcomes for patients with CMR.
Fertility preservation in lymphoma patients treated with immunochemotherapy regimens with or without radiotherapy: results of a retrospective multicenter Italian study (Ferty care).
Leuk Lymphoma
October 2024
Article Synopsis
- - The study examined fertility preservation methods in 414 female lymphoma patients aged 18-40 diagnosed between 2010 and 2018, with most common cancer types being Hodgkin Lymphoma (74%) and various others.
- - Majority of the patients (71%) received ABVD as the first-line treatment, while fertility preservation strategies included GnRHa (78%), oral contraceptives, and cryopreservation of oocytes and ovarian tissue.
- - After treatment, 70% of women had regular menstrual cycles, 8% experienced premature ovarian failure, and there were 43 pregnancies observed during a median follow-up of 5 years, with age and treatment intensity being significant factors for amenorrhea and POF.
Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the real-world persistence rate, patterns of use, and clinical outcomes in 309 patients with CLL receiving single-agent ibrutinib in first line (1L, = 118), 2L ( = 127) and ≥3L ( = 64) in the prospective, real-world, Italian EVIdeNCE study. After a median follow-up of 23.
View Article and Find Full Text PDFArticle Synopsis
- Vaccinations play a crucial role in preventing infectious diseases, particularly for immunocompromised individuals like those with non-Hodgkin lymphomas (NHLs).
- The COVID-19 pandemic highlighted the need for effective vaccinations to prevent severe complications in NHL patients, but studies show reduced vaccine responses after treatment with anti-CD20 monoclonal antibodies.
- This review discusses the effectiveness of COVID-19 and other vaccines in NHL patients and suggests team-based strategies for better vaccine management in these individuals.